SLAMF7 and plasma cell myeloma: Elotuzumab is a humanized IgG1 mAb that induces NK cell activation by binding to SLAM family member 7 (SLAMF7) (also known as CS1), which is highly expressed on NK cells, plasma cells, and myeloma cells (>95%) [80].